Chichi Udochi
Internal Medicine · Washington, DCNPI 1477016517
Payments from drug & device makers
Across 87 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$425
- Astellas Pharma US Inc$295
- AbbVie$184
- Lilly USA, LLC$143
- Novo Nordisk$142
- Corcept Therapeutics$127
- plus $407 from 11 others
What the payments were for
- Food & beverage$1,62494%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 23 | $425 |
| Astellas Pharma US Inc | 9 | $295 |
| AbbVie | 14 | $184 |
| Lilly USA, LLC | 7 | $143 |
| Novo Nordisk | 8 | $142 |
| Corcept Therapeutics | 6 | $127 |
| Gilead | 4 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $65 |
| Merck | 2 | $53 |
| Johnson & Johnson | 3 | $50 |
| AstraZeneca | 2 | $41 |
| Boston Scientific | 1 | $31 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Medtronic | 1 | $17 |
| Pfizer | 1 | $13 |
How this compares
$1,724 in reported general payments places this provider in the 80th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 11 | $114 |
| Losartan Potassium | 11 | $66 |
| Amlodipine Besylate | 14 | $61 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Washington
- Federico AschWashington$4.6M
- Geoffrey GibneyWashington$2.3M
- Nnemdi Kamanu EliasWashington$939K
- Andrea SingerWashington$930K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$454K
- Ida BergstromWashington$295K
- Miriam CameronWashington$290K
- Bruce RashbaumWashington$265K
- Kevin GriffithsWashington$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.